Themis Medicare Ltdinformed the exchange that it had received approval from the Drug Controller General of India (DCGI) for import & marketing of Remifentanil 1 mg/2mg Powder for Concentrate for Solution for Injection.
The drug been approved for use as an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures, and for continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting, and as an analgesic component of monitored anesthesia care in adult patients.
Themis will market this drug with the brand name REMITHEM®.